{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-26-000092","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2026-06-11T20:52:12+00:00","discovered_at":"2026-06-11T20:53:00.415870+00:00","generated_at":"2026-06-11T20:53:10.198904+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Pliant Therapeutics annual meeting approves all proposals; say-on-pay passes with narrow margin","bullets":["Elected Class III directors Coulie, Crowell, and Krognes with 18.8M, 18.2M, and 19.3M votes for respectively.","Advisory vote on executive compensation approved: 15.3M for, 14.6M against, 0.8M abstain; 11.9M broker non-votes.","Ratification of Deloitte as independent auditor for FY2026 passed with 41.7M for, 0.7M against, 69K abstain.","Approximately 61.9M shares outstanding; broker non-votes totaled 11.9M on director and say-on-pay proposals."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-26-000092","json":"https://secwatch.observer/filing/0001746473-26-000092.json","markdown":"https://secwatch.observer/filing/0001746473-26-000092.md","text":"https://secwatch.observer/filing/0001746473-26-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000092/0001746473-26-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000092/plrx-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:53:10.198904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"682fefef8c14cda372c80a07bae1914b0827253d","claim":"PLIANT THERAPEUTICS, INC. shareholders approved Election of three Class III directors to serve until the 2029 Annual Meeting at the 2026-06-11 meeting.","evidence_excerpt":"Proposal No. 1: The Company’s stockholders approved the election of each of the aforementioned Class III director nominees to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. The voting results are as follows: Nominee For Withhold Bernard Coulie, M.D., Ph.D., MBA 18,824,540 11,807,308 Gayle Crowell 18,186,914 12,444,934 Steve Krognes, MBA 19,299,728 11,332,120 The broker non-votes for Proposal No. 1 totaled 11,895,135 shares of common stock.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000092/0001746473-26-000092-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"a8663d2eca379ed96ba31786cd881c26c76623fb","claim":"PLIANT THERAPEUTICS, INC. shareholders approved Non-binding advisory vote to approve the compensation of the Company’s named executive officers at the 2026-06-11 meeting.","evidence_excerpt":"Proposal No. 2: The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The voting results are as follows: For Against Abstain 15,282,788 14,572,455 776,605 The broker non-votes for Proposal No. 2 totaled 11,895,135 shares of common stock.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000092/0001746473-26-000092-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"a9900def3b330e6204718c3d15a08bae3e6fdef4","claim":"PLIANT THERAPEUTICS, INC. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.","evidence_excerpt":"Proposal No. 3: The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results are as follows: For Against Abstain 41,710,604 747,140 69,239 There were no broker non-votes for Proposal No. 3.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000092/0001746473-26-000092-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}